Helicobacter pylori-colonized mongolian gerbils, method for preparation
thereof, and method for screening anti-Helicobacter pylori substance
using them
    1.
    发明授权
    Helicobacter pylori-colonized mongolian gerbils, method for preparation thereof, and method for screening anti-Helicobacter pylori substance using them 失效
    幽门螺杆菌定殖的蒙古沙鼠,其制备方法,幽门螺杆菌分离培养基及使用它们的抗幽门螺杆菌物质筛选方法

    公开(公告)号:US5929299A

    公开(公告)日:1999-07-27

    申请号:US693100

    申请日:1996-08-09

    摘要: Helicobacter pylori-colonized Mongolian gerbils prepared by oral inoculation of a broth culture obtained from a liquid culture of Helicobacter pylori, to the Mongolian gerbils for intragastric colonization of Helicobacter pylori. These Mongolian gerbil models are useful for screening the therapeutic efficacies of drugs against Helicobacter pylori, as well as elucidation of pathology of Helicobacter pylori disease in humans. Moreover, the medium of the present invention for isolating Helicobacter pylori, which is supplemented with vancomycin, trimethoprim, amphotericin B, polymyxin B and 2,3,5-triphenyltetrazolium chloride, enables selective and efficient detection of Helicobacter pylori colonized in their Mongolian gerbils which have microorganisms living in stomach. A combined use of the above-mentioned Mongolian gerbil models and the medium for isolating Helicobacter pylori enables screening of an anti-Helicobacter pylori substance at an animal levels thereby enabling accurate prediction of clinical effects of the anti-Helicobacter pylori substance.

    摘要翻译: PCT No.PCT / JP95 / 02531 Sec。 371日期:1996年8月9日 102(e)日期1996年8月9日PCT提交1995年12月8日PCT公布。 第WO96 / 18291号公报 日期1996年6月20日幽门螺杆菌定殖的蒙古沙鼠通过口服接种从幽门螺杆菌液体培养物获得的肉汤培养物制备成蒙古沙鼠用于幽门螺杆菌胃内定殖。 这些蒙古沙鼠模型可用于筛选药物对幽门螺杆菌的治疗功效,以及阐明人幽门螺杆菌病的病理学。 此外,本发明的用于分离补充有万古霉素,甲氧苄氨嘧啶,两性霉素B,多粘菌素B和2,3,5-三苯基四氮唑氯化物的幽门螺杆菌的培养基能够选择性和有效地检测在其蒙古沙鼠中定居的幽门螺杆菌, 有微生物住在胃里。 综合使用上述的蒙古沙鼠模型和用于分离幽门螺杆菌的培养基使得能够以动物水平筛选抗幽门螺杆菌物质,从而能够准确预测抗幽门螺杆菌物质的临床效果。

    Prophylactic or therapeutic agent for diseases attributable to infection with helicobacters
    2.
    发明授权
    Prophylactic or therapeutic agent for diseases attributable to infection with helicobacters 失效
    预防或治疗由于感染直接感染的疾病

    公开(公告)号:US06221864B1

    公开(公告)日:2001-04-24

    申请号:US09446662

    申请日:1999-12-23

    IPC分类号: A61K315377

    CPC分类号: A61K31/5377 A61K31/535

    摘要: The present invention relates to an agent for the prophylaxis and treatment of diseases caused by Helicobacter infections, which comprises (S)-1-cyclopropyl-1,4-dihydro-7-[2-(N,N-dimethylaminomethyl)morpholino]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof. The prophylactic and therapeutic agent of the present invention is effective even when used alone in a small dose for a short time, is almost free of problematic side effects such as tolerance and diarrhea, and is low toxic and capable of safe and ensured bacterial eradication. It is useful for the prophylaxis and treatment of diseases caused by Helicobacter infections, particularly, gastritis, gastric ulcer, duodenal ulcer, malignant lymphoma and gastric cancer.

    摘要翻译: 本发明涉及一种用于预防和治疗由幽门螺杆菌感染引起的疾病的药剂,其包含(S)-1-环丙基-1,4-二氢-7- [2-(N,N-二甲基氨基甲基)吗啉代] 6-氟-8-甲氧基-4-氧代喹啉-3-羧酸或其药学上可接受的盐。 本发明的预防和治疗剂即使在短时间内以小剂量单独使用也是有效的,几乎没有诸如耐受性和腹泻的副作用,并且毒性低,能够安全和确保细菌根除。 可用于预防和治疗由幽门螺杆菌感染引起的疾病,特别是胃炎,胃溃疡,十二指肠溃疡,恶性淋巴瘤和胃癌。